GGrantIndex
← Leaderboards

Robert A. Wise

Johns Hopkins University

$33,179,807
Attributed
$46,283,705
Total exposure
16
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.8M · FY200522
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$61,428,149 · 17

By mechanism

P50$19,427,453 · 4
U01$19,388,002 · 7
T32$19,231,645 · 1
R01$2,362,741 · 1
R34$735,125 · 1
U10$283,183 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchClinical TrialsLungPharmaceutical PreparationsInflammationPlacebosRandomizedQuality Of LifeHuman Therapy EvaluationHuman SubjectResearch PersonnelMonitorParticipantAsthmaUnited StatesSymptomsUnited States National Institutes Of HealthMorbidity - Disease RateProgramsChronic Obstructive Airway DiseaseOutcome MeasureDesignLung DiseasesPlacebo Control

Grant awards (82)

Multidisciplinary Training Program in Lung Disease$689,234
T32 · FY2022 · HL
Multidisciplinary Training Program in Lung Disease$1,291,206
T32 · FY2021 · HL
Multidisciplinary Training Program in Lung Disease$1,271,856
T32 · FY2020 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$1,214,824
T32 · FY2019 · HL · contact PI
Effect of Losartan on Progression of Emphysema$364,499
U01 · FY2019 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$1,174,872
T32 · FY2018 · HL · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2018 · HL · contact PI
Pilot Study of Zinc Acetate for Chronic Cough$163,750
R34 · FY2018 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$978,656
T32 · FY2017 · HL · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2017 · HL · contact PI
Pilot Study of Zinc Acetate for Chronic Cough$286,125
R34 · FY2017 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$3,072
T32 · FY2017 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$1,216,180
T32 · FY2016 · HL · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2016 · HL · contact PI
Pilot Study of Zinc Acetate for Chronic Cough$285,250
R34 · FY2016 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$1,033,188
T32 · FY2015 · HL · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2015 · HL · contact PI
Multidisciplinary Training Program in Lung Disease$1,015,653
T32 · FY2014 · HL · contact PI
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients wit*$1,887,086
U01 · FY2013 · HL
Multidisciplinary Training Program in Lung Disease$1,011,687
T32 · FY2013 · HL · contact PI
Study of Asthma and Nasal Steroids (STAN)$74,665
U01 · FY2013 · HL · contact PI
Study of Soy Isoflavones in Asthma (SOYA)$56,325
U01 · FY2013 · HL · contact PI
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients wit*$1,955,869
U01 · FY2012 · HL
Enhancing Nrf2 by Sulforaphane Treatment in COPD$1,936,131
U01 · FY2012 · HL · contact PI
Developing Nrf2 as a target for treatment of corticosteroid resistance in COPD$452,627
P50 · FY2012 · HL · contact PI
Study of Asthma and Nasal Steroids (STAN)$409,801
U01 · FY2012 · HL · contact PI
Study of Soy Isoflavones in Asthma (SOYA)$354,589
U01 · FY2012 · HL · contact PI
MECHANISMS AND TREATMENT OF COPD PROGRESSION$3,125,930
P50 · FY2011 · HL · contact PI
Enhancing Nrf2 by Sulforaphane Treatment in COPD$1,968,486
U01 · FY2011 · HL · contact PI
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients wit*$1,108,104
U01 · FY2011 · HL
Multidisciplinary Training Program in Lung Diseases$753,574
T32 · FY2011 · HL · contact PI
Novel Treatments to Prevent COPD Progression$546,021
P50 · FY2011 · HL · contact PI
Developing Nrf2 as a target for treatment of corticosteroid resistance in COPD$458,801
P50 · FY2011 · HL · contact PI
Study of Asthma and Nasal Steroids (STAN)$409,884
U01 · FY2011 · HL · contact PI
Study of Soy Isoflavones in Asthma (SOYA)$356,139
U01 · FY2011 · HL · contact PI
Administrative Core$113,688
P50 · FY2011 · HL · contact PI
MECHANISMS AND TREATMENT OF COPD PROGRESSION$3,098,720
P50 · FY2010 · HL · contact PI
Multidisciplinary Training Program in Lung Diseases$1,102,892
T32 · FY2010 · HL · contact PI
Enhancing Nrf2 by Sulforaphane Treatment in COPD$1,087,246
U01 · FY2010 · HL · contact PI
Novel Treatments to Prevent COPD Progression$547,508
P50 · FY2010 · HL · contact PI
Study of Asthma and Nasal Steroids (STAN)$409,812
U01 · FY2010 · HL · contact PI
Study of Soy Isoflavones in Asthma (SOYA)$365,933
U01 · FY2010 · HL · contact PI
Administrative Core$113,638
P50 · FY2010 · HL · contact PI
MECHANISMS AND TREATMENT OF COPD PROGRESSION$3,041,763
P50 · FY2009 · HL · contact PI
Multidisciplinary Training Program in Lung Diseases$1,094,779
T32 · FY2009 · HL · contact PI
Novel Treatments to Prevent COPD Progression$605,603
P50 · FY2009 · HL · contact PI
Study of Soy Isoflavones in Asthma (SOYA)$530,745
U01 · FY2009 · HL · contact PI
Study of Asthma and Nasal Steroids (STAN)$409,724
U01 · FY2009 · HL · contact PI
Administrative Core$112,986
P50 · FY2009 · HL · contact PI
MECHANISMS AND TREATMENT OF COPD PROGRESSION$2,908,696
P50 · FY2008 · HL · contact PI
Multidisciplinary Training Program in Lung Diseases$1,086,744
T32 · FY2008 · HL · contact PI
Novel Treatments to Prevent COPD Progression$568,708
P50 · FY2008 · HL · contact PI
Administrative Core$110,585
P50 · FY2008 · HL · contact PI
MECHANISMS AND TREATMENT OF COPD PROGRESSION$2,969,335
P50 · FY2007 · HL · contact PI
Multidisciplinary Training Program in Lung Diseases$1,086,744
T32 · FY2007 · HL · contact PI
Clinical Trial of Acid Reflux Therapy in Asthma$662,283
U01 · FY2007 · HL · contact PI
Novel Treatments to Prevent COPD Progression$532,137
P50 · FY2007 · HL · contact PI
Administrative Core$120,707
P50 · FY2007 · HL · contact PI
Multidisciplinary Training Program in Lung Diseases$990,939
T32 · FY2006 · HL · contact PI
Clinical Trial of Acid Reflux Therapy in Asthma$772,866
U01 · FY2006 · HL · contact PI
Multidisciplinary Training Program in Lung Diseases$1,108,045
T32 · FY2005 · HL
Clinical Trial of Acid Reflux Therapy in Asthma$791,142
U01 · FY2005 · HL
The Placebo Effect in Asthma$515,972
R01 · FY2005 · HL
Multidisciplinary Training Program in Lung Diseases$1,107,500
T32 · FY2004 · HL
Clinical Trial of Acid Reflux Therapy in Asthma$783,078
U01 · FY2004 · HL
The Placebo Effect in Asthma$693,443
R01 · FY2004 · HL
Clinical Trial of Acid Reflux Therapy in Asthma$736,466
U01 · FY2003 · HL
The Placebo Effect in Asthma$667,759
R01 · FY2003 · HL
SCLERODERMA LUNG STUDY$70,179
U01 · FY2003 · HL
The Placebo Effect in Asthma$485,567
R01 · FY2002 · HL
SCLERODERMA LUNG STUDY$144,555
U01 · FY2002 · HL
LUNG HEALTH STUDY--LONG TERM FOLLOW UP$34,699
U10 · FY2002 · HL
BONE MINERAL DENSITY AND INHALED CORTICOSTEROIDS &COPD$0
M01 · FY2002 · RR
INHALED CORTICOSTEROIDS /ADRENAL FUNCTION IN COPD PATIENTS$0
M01 · FY2002 · RR
SCLERODERMA LUNG STUDY$141,636
U01 · FY2001 · HL
LUNG HEALTH STUDY--LONG TERM FOLLOW UP$126,111
U10 · FY2001 · HL
BONE MINERAL DENSITY AND INHALED CORTICOSTEROIDS &COPD$0
M01 · FY2001 · RR
INHALED CORTICOSTEROIDS /ADRENAL FUNCTION IN COPD PATIENTS$0
M01 · FY2001 · RR
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$142,759
U01 · FY2000 · HL
LUNG HEALTH STUDY--LONG TERM FOLLOW UP$122,373
U10 · FY2000 · HL
BONE MINERAL DENSITY AND INHALED CORTICOSTEROIDS &COPD$0
M01 · FY2000 · RR
ADRENAL FUNCTION IN PTS TAKING INHALED CORTICOSTEROIDS$0
M01 · FY2000 · RR